# Eos

> Eos is a VC fund in Saint Andrews backing Biotechnology and Health Care. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Saint Andrews, United Kingdom
- Total investments: 11
- Last investment: Jun 2025
- Lead investor: 64%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/eos-advisory/
- Website: https://eos-advisory.com/

Eos is a VC fund in Saint Andrews focused on Biotechnology and Health Care. Eos Advisory is focused on providing seed funding to ventures based upon strong and innovative science, technology and engineering.

## Contacts

5 contacts available for Eos. Shizune tracks 2 team members at Eos. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/eos-7f20?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 5 | 45% |
| Health Care | 3 | 27% |
| Medical | 2 | 18% |
| Therapeutics | 2 | 18% |
| Manufacturing | 2 | 18% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 7 | 64% |
| Funding Round | 2 | 18% |
| Series A | 1 | 9% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anne Muir | Director of Portfolio | 1 | https://shizune.co/investors/profile/anne-muir-9063 |
| Kevin Grainger | Founder and Chairman | 2 | https://shizune.co/investors/profile/kevin-grainger |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Laverock Therapeutics | Laverock Therapeutics is a biotechnology company developing programmable gene control technologies for advanced cell and gene therapies. The company builds a platform that uses endogenous microRNA and gene regulatory mechanisms to enable precise, tunable control of gene expression, allowing engineered cells to activate or silence therapeuticfunctions in response to specific biological signals. Its core approach focuses on “disease-responsive” therapies, where engineered cells are designed to sense the surrounding cellular environment and adjust their activity accordingly. This enables therapies that can switch on or off, or modulate activity levels, depending on disease state or tissue context, rather than operating in a constant active mode. The company’s platform supports multiplex gene control, meaning multiple genes can be regulated simultaneously within engineered cells. This capability is applied to developing next-generation cell therapies such as CAR-T cells and macrophages for oncology, as well as exploratory programs in genetic, inflammatory, and metabolic diseases. |  | Seed | Jun 30, 2025 |  |
| Dxcover | Dxcover is a clinical-stage liquid biopsy firm that is developing diagnostics for the early diagnosis of numerous malignancies, when treatment has a better possibility of having an influence on outcomes. The business was the first to use infrared spectroscopy of circulating pan-omic indicators to detect and identify cancer. The business hasgenerated compelling clinical data on the diagnosis of Stage I and Stage II malignancies with high accuracy.Dxcover was established in 2016 in Glasgow, Glasgow City by David S Palmer, Holly Butler, and Matthew Baker. | $6.2M |  | Feb 03, 2025 |  |
| Concinnity Genetics | Concinnity Genetics transforms the safety of gene therapies by designing novel control mechanisms using an AI platform. | $3.8M | Seed | Dec 16, 2024 |  |
| Biotangents | Biotangents was founded upon their Leapfrog Assembly™ platform technology for building complex genetic constructs from multiple DNA parts. This was developed through a SMART: Scotland award from Scottish Enterprise and was exe0mplified through the generation of their terpenoid biosynthesis strains. During that successful first year they alsodeveloped their DNA randomisation technology, Short Sequence Randomisation™.In 2016, having formulated a concept for a modular cell-free nucleic acid detection technology, Moduleic Sensing™, and with support from SynbiCITE, they commenced development of their first diagnostic test, a highly specific and sensitive solution for pen-side diagnosis of infectious diseases in livestock. | $2.9M | Venture - Series Unknown | Nov 28, 2024 |  |
| Naturbeads | Naturbeads, a company working to manufacture a replacement to the ocean-polluting microbeads that are found in many personal and home care products and paints. Naturbeads proposes a biodegradable alternative to plastic microbeads that could mitigate micro plastic pollution in the oceans and soil. The technology to create the cellulose microbeadswas developed at the University of Bath by Professors Janet Scott and Davide Mattia from the Centre for Sustainable Chemical Technologies in 2017 | $9.9M | Series A | Nov 14, 2024 |  |
| Chromacity | Chromacity Lasers is a spin-out from Heriot-Watt University, one of the UK’s leading technical universities with a focus on photonics. Their founding team has over 40 years’ experience in ultrafast lasers and fiber lasers. They have developed wavelength tunable femtosecond lasers from the ultraviolet (400 nm) to the mid-infrared (> 6 µm) forindustrial and scientific applications in fluorescence microscopy, gas spectroscopy, laser material processing and semiconductor engineering.Robust, patent-pending femtosecond fiber-laser technology underpins every product, delivering reliable, turn-key performance. But they don’t stop there: their embedded web server provides a uniquely simple control interface, allowing wireless operation from any laptop, tablet or smartphone.Their focus is on manufacturing femtosecond lasers for life-sciences applications. In parallel with these core products, they work with systems manufacturers to provide custom OEM femtosecond and picosecond lasers optimized for specific applications in engineering and materials processing. They can provide combinations of pulse repetition rate, energy and wavelength not available from any other manufacturers. | $1.3M | Seed | Jul 31, 2024 |  |
| Nami Surgical | Nami Surgical provides robotic surgery technology solutions to enhance patient care while giving surgeons intuitive, high-performance moveable instruments. | $3.1M | Seed | May 08, 2024 |  |
| Neupulse | Neupulse is the brand of Neurotherapeutics LtdThe direction of our current research was very much shaped by the feedback we received from individuals with tic disorders and their families.When we asked them for their thoughts on our research priorities we were frequently told that what was really needed was a safe and effective non-drugtreatment for tic disorder that could be used outside of the clinic and gave individuals control over their tics. This led directly to us focusing on the use of peripheral nerve stimulation as a means of bringing about changes in the brain networks associated with the production of tics. We demonstrated that delivering rhythmic patterns of mild electrical stimulation to the median nerve at the wrist could be used to increase the power and the synchronicity of the brain oscillations (rhythms) associated with the suppression of movements, and that this type of stimulation was sufficient to dramatically reduce the frequency of tics and remove the urge-to-tic in individuals with tic disorders.Importantly, we also showed that this type of stimulation did not materially affect the execution of volitional (intentional) movements or impair cognitive functions such as attention. | $3.2M | Seed | Mar 18, 2024 |  |
| Wobble Genomics | Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers. | $10.9M | Seed | Mar 07, 2024 |  |
| Carcinotech | Carcinotech is focused on treating cancers and is based at the Roslin Innovation Centre on the outskirts of Edinburgh. | $5.3M | Seed | Jan 29, 2024 |  |

10 of 11 investments shown.

## Co-investors
- [Eos](https://shizune.co/investors/profile/eos-advisory) — VC Fund, 13 deals together
- [Maven Capital Partners](https://shizune.co/investors/profile/maven-capital-partners) — VC Fund, 7 deals together
- [Scottish Enterprise](https://shizune.co/investors/profile/scottish-enterprise) — VC Fund, 5 deals together
- [SIS Ventures](https://shizune.co/investors/profile/sis-ventures) — VC Fund, 4 deals together
- [Calculus Capital](https://shizune.co/investors/profile/calculus-capital) — VC Fund, 3 deals together
- [Kelvin Capital](https://shizune.co/investors/profile/kelvin-capital) — VC Fund, 3 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Eos invest in?

Eos invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Funding Round stage. Most of the 11 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Eos?

Public channels for Eos include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Eos?

The team at Eos includes Anne Muir (Director of Portfolio) and Kevin Grainger (Founder and Chairman). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co